BR112019007271A2 - compostos de quinoxalina como inibidores do receptor da tirosina quinase do tipo iii - Google Patents

compostos de quinoxalina como inibidores do receptor da tirosina quinase do tipo iii Download PDF

Info

Publication number
BR112019007271A2
BR112019007271A2 BR112019007271A BR112019007271A BR112019007271A2 BR 112019007271 A2 BR112019007271 A2 BR 112019007271A2 BR 112019007271 A BR112019007271 A BR 112019007271A BR 112019007271 A BR112019007271 A BR 112019007271A BR 112019007271 A2 BR112019007271 A2 BR 112019007271A2
Authority
BR
Brazil
Prior art keywords
methoxy
carbonitrile
amino
quinoxaline
phenyl
Prior art date
Application number
BR112019007271A
Other languages
English (en)
Portuguese (pt)
Inventor
Ho Chen-Hsuan
Liao Chu-Bin
Huang Hung-Jyun
Chen Hung-Kai
Peng Shao-Zheng
Chiou Shian-Yi
Original Assignee
Dev Ct Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dev Ct Biotechnology filed Critical Dev Ct Biotechnology
Publication of BR112019007271A2 publication Critical patent/BR112019007271A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
    • C07D241/52—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112019007271A 2016-10-10 2017-10-09 compostos de quinoxalina como inibidores do receptor da tirosina quinase do tipo iii BR112019007271A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662406328P 2016-10-10 2016-10-10
PCT/US2017/055809 WO2018071348A1 (en) 2016-10-10 2017-10-09 Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112019007271A2 true BR112019007271A2 (pt) 2019-09-17

Family

ID=61905910

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019007271A BR112019007271A2 (pt) 2016-10-10 2017-10-09 compostos de quinoxalina como inibidores do receptor da tirosina quinase do tipo iii

Country Status (13)

Country Link
US (1) US10689362B2 (enExample)
EP (1) EP3523285A4 (enExample)
JP (1) JP7206188B2 (enExample)
KR (1) KR102609813B1 (enExample)
CN (1) CN110325515B (enExample)
AU (1) AU2017342928B2 (enExample)
BR (1) BR112019007271A2 (enExample)
CA (1) CA3039919A1 (enExample)
IL (1) IL265829B (enExample)
RU (1) RU2019113764A (enExample)
SG (1) SG11201903091VA (enExample)
TW (1) TWI648266B (enExample)
WO (1) WO2018071348A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4214198A4 (en) * 2020-09-21 2024-10-09 Hutchison Medipharma Limited Heteroaromatic compounds and uses thereof
JP2024515976A (ja) * 2021-04-26 2024-04-11 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 骨格再生のための機能不全骨格幹細胞の生化学的活性化
WO2023082145A1 (en) * 2021-11-11 2023-05-19 4B Technologies (Suzhou) Limited Intermediate compound of quinoxaline and preparation process thereof
CN114605391B (zh) * 2022-02-21 2024-01-26 广州六顺生物科技股份有限公司 喹喔啉类衍生物及其制备方法和应用
CN115141177B (zh) * 2022-08-30 2022-12-09 福贝生物科技(苏州)有限公司 喹喔啉类化合物马来酸盐的新晶型及其制备方法
WO2025019622A2 (en) * 2023-07-18 2025-01-23 Elixiron Immunotherapeutics Inc. Method of enhanced absorption of quinoxaline type iii receptor tyrosine kinase inhibitors
WO2025067450A1 (zh) * 2023-09-28 2025-04-03 福贝生物医药科技(北京)有限公司 一种固体分散体、药物组合物、其制备方法及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0860433B1 (en) * 1995-11-07 2002-07-03 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
WO2000023444A1 (en) * 1998-10-21 2000-04-27 Abbott Laboratories 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
US7304092B1 (en) * 2002-11-12 2007-12-04 Yale University Compounds and methods for treating tumors, cancer and hyperproliferative diseases
FR2856686A1 (fr) * 2003-06-25 2004-12-31 Sod Conseils Rech Applic Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
CN101432281B (zh) * 2006-04-19 2013-08-28 诺瓦提斯公司 6-0-取代的苯并*唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法
JP5328640B2 (ja) * 2006-04-19 2013-10-30 ノバルティス アーゲー ６−ｏ−置換ベンゾオキサゾールおよびベンゾチアゾール化合物ならびにｃｓｆ−１ｒシグナル伝達を阻害する方法
WO2008063888A2 (en) * 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
NZ588511A (en) * 2008-05-23 2012-04-27 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
EP2473498A1 (en) * 2009-09-04 2012-07-11 Bayer Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
GB201007286D0 (en) * 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) * 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
EP2806874B1 (en) * 2012-01-25 2017-11-15 Neupharma, Inc. Quinoxaline-oxy-phenyl derivatives as kinase inhibitors
PL2840080T3 (pl) * 2012-04-17 2018-06-29 Fujifilm Corporation Zawierający azot związek heterocykliczny lub jego sól
WO2014075077A1 (en) * 2012-11-12 2014-05-15 Neupharma, Inc. Certain chemical entities, compositions, and methods
WO2016077632A2 (en) * 2014-11-13 2016-05-19 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications

Also Published As

Publication number Publication date
CN110325515B (zh) 2023-06-20
IL265829A (en) 2019-06-30
TWI648266B (zh) 2019-01-21
KR102609813B1 (ko) 2023-12-07
CN110325515A (zh) 2019-10-11
JP2019530708A (ja) 2019-10-24
TW201817720A (zh) 2018-05-16
WO2018071348A1 (en) 2018-04-19
CA3039919A1 (en) 2018-04-19
RU2019113764A (ru) 2020-11-13
US20190308949A1 (en) 2019-10-10
EP3523285A1 (en) 2019-08-14
KR20190059959A (ko) 2019-05-31
AU2017342928B2 (en) 2021-09-09
EP3523285A4 (en) 2020-04-22
JP7206188B2 (ja) 2023-01-17
IL265829B (en) 2022-06-01
US10689362B2 (en) 2020-06-23
RU2019113764A3 (enExample) 2021-01-29
SG11201903091VA (en) 2019-05-30
AU2017342928A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
BR112019007271A2 (pt) compostos de quinoxalina como inibidores do receptor da tirosina quinase do tipo iii
TWI345567B (en) Benzimidazole quinolinones and uses thereof
KR101473662B1 (ko) 피리도피라진 유도체 및 신호 전달 경로의 조절제로서의 이의 용도
CA2853401C (en) Anticancer benzopyrazines via the inhibition of fgfr kinases
BR112012011287B1 (pt) Compostos inibidores de cinase derivados de pirolopirimidina, sua formulação farmacêutica e seus usos
BR112019018991A2 (pt) compostos e composições para tratar distúrbios hematológicos
AU2011334624A1 (en) Substituted benzopyrazin derivatives as FGFR kinase inhibitors for the treatment of cancer diseases
MXPA06004194A (es) Inhibicion de fgfr3 y tratamiento de mieloma multiple.
DK2930167T3 (en) INDOLINO DERIVATIVE AS A TYROSINKINASE INHIBITOR
BR112014023460B1 (pt) Composto, formulação farmacêutica, uso de um composto
CA3240011A1 (en) Fused thiazolopyrimidine derivatives as mnks inhibitors
KR102319676B1 (ko) 피롤로피리미딘, 피롤로피리딘, 인다졸 화합물 유도체 및 이를 포함하는 치료용 약학 조성물
CN1976706B (zh) 抑制fgfr3及治疗多发性骨髓瘤
TWI759829B (zh) 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
RU2833004C2 (ru) Производные гетероциклического пиразола как ингибиторы рецепторной тирозикиназы типа III
HK40012508B (en) Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors
HK40012508A (en) Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors
CN118355012A (zh) 表现出癌细胞生长抑制效果的新型杂环取代嘧啶衍生物以及含有其的药物组合物
KR20250154499A (ko) Parp 억제제로서의 치환된 질소-함유 트리시클릭 화합물 및 이의 용도

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 241/40 , C07D 241/44 , C07D 401/12

Ipc: C07D 241/40 (2006.01), C07D 241/44 (2006.01), C07D

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements